|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Amylin Pharmaceuticals Inc., of San Diego, initiated the first Phase II study of the AC2993 LAR development program. The goal of the program is the development of a once-a-month injection of Amylin's drug candidate AC2993, or synthetic exendin-4, as a treatment for Type II diabetes. The double-blind, placebo-controlled, multicenter study will focus on safety and tolerability, as well as the pharmacokinetic profiles of rising doses of two formulations of AC2993. The study also will examine effects of AC2993 LAR on fructosamine, HbA1c and fasting and post-meal glucose concentrations. AC2993 is a 39-amino-acid peptide.
Applied Genetics Inc. Dermatics, of Freeport, ...